BR112015008376A2 - conjugados fármaco-proteína - Google Patents

conjugados fármaco-proteína

Info

Publication number
BR112015008376A2
BR112015008376A2 BR112015008376A BR112015008376A BR112015008376A2 BR 112015008376 A2 BR112015008376 A2 BR 112015008376A2 BR 112015008376 A BR112015008376 A BR 112015008376A BR 112015008376 A BR112015008376 A BR 112015008376A BR 112015008376 A2 BR112015008376 A2 BR 112015008376A2
Authority
BR
Brazil
Prior art keywords
drug
conjugates
protein conjugates
peptide
binding protein
Prior art date
Application number
BR112015008376A
Other languages
English (en)
Inventor
Godwin Antony
Badescu George
Burt John
Frigerio Mark
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of BR112015008376A2 publication Critical patent/BR112015008376A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "conjugados fármaco-proteína”. a invenção descreve conjugados específicos contendo auristatinas e uma proteína ou peptídio de ligação, e processo para fazer os mesmos. os conjugados utilizam a tecnologia de ligante específico que oferece vantagens em relação aos conjugados anticorpo-fármaco conhecidos. também estão descritos conjugados específicos de fármacos e uma proteína ou peptídio de ligação onde mais de uma cópia do fármaco está presente.
BR112015008376A 2012-10-24 2013-10-11 conjugados fármaco-proteína BR112015008376A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US201261717710P 2012-10-24 2012-10-24
US201361811285P 2013-04-12 2013-04-12
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/052661 WO2014064423A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (1)

Publication Number Publication Date
BR112015008376A2 true BR112015008376A2 (pt) 2017-09-26

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008376A BR112015008376A2 (pt) 2012-10-24 2013-10-11 conjugados fármaco-proteína

Country Status (19)

Country Link
US (2) US20150290342A1 (pt)
EP (2) EP3159013A1 (pt)
JP (1) JP6328648B2 (pt)
KR (1) KR102209395B1 (pt)
CN (1) CN104870021B (pt)
AU (1) AU2013336409B2 (pt)
BR (1) BR112015008376A2 (pt)
CA (1) CA2884299A1 (pt)
DK (1) DK2911700T5 (pt)
ES (1) ES2623209T3 (pt)
HK (1) HK1208187A1 (pt)
IL (1) IL237672B (pt)
IN (1) IN2015DN02349A (pt)
MX (1) MX2015005122A (pt)
MY (1) MY169147A (pt)
RU (1) RU2015119561A (pt)
SG (1) SG11201501618WA (pt)
WO (1) WO2014064423A1 (pt)
ZA (1) ZA201501642B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658240A (zh) * 2013-06-04 2016-06-08 西托姆克斯治疗公司 用于缀合可活化抗体的组合物和方法
CA2921707C (en) 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
JP6721572B2 (ja) * 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
MY177148A (en) * 2014-06-12 2020-09-08 Cspc Megalith Biopharmaceutical Co Ltd Homogenous antibody drug conjugates via enzymatic methods
WO2016059377A1 (en) * 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
MX2017005199A (es) * 2014-10-24 2017-07-26 Polytherics Ltd Conjugados y reactivos de conjugacion.
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
CN109152845B (zh) 2016-04-14 2022-07-12 宝力泰锐克斯有限公司 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
WO2017212250A1 (en) * 2016-06-06 2017-12-14 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
JP2023521920A (ja) * 2020-04-15 2023-05-25 シェンチェン・エンデュアリング・バイオテック・リミテッド 抗体－薬物コンジュゲート
EP4308163A1 (en) * 2021-03-19 2024-01-24 Shenzhen Enduring Biotech, Ltd. Pegylated t cell engager with dual specificities to cd3 and cd19
WO2023141855A1 (en) * 2022-01-27 2023-08-03 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
US7968687B2 (en) * 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
PL2842575T3 (pl) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Koniugaty aurystatyny lek łącznik
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
WO2010120561A1 (en) * 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
US9995804B2 (en) * 2012-04-25 2018-06-12 Koninklijke Philips N.V. System and method for locating a gradient coil
KR20150023027A (ko) * 2012-06-19 2015-03-04 폴리테릭스 리미티드 항체 접합체의 제조를 위한 신규한 공정 및 신규한 항체 접합체

Also Published As

Publication number Publication date
WO2014064423A1 (en) 2014-05-01
JP6328648B2 (ja) 2018-05-23
AU2013336409A1 (en) 2015-04-02
EP3159013A1 (en) 2017-04-26
ZA201501642B (en) 2016-01-27
EP2911700B1 (en) 2017-02-08
CA2884299A1 (en) 2014-05-01
CN104870021A (zh) 2015-08-26
RU2015119561A (ru) 2016-12-20
DK2911700T5 (en) 2017-05-22
CN104870021B (zh) 2018-03-13
HK1208187A1 (en) 2016-02-26
KR20150103656A (ko) 2015-09-11
JP2015533847A (ja) 2015-11-26
US20220062436A1 (en) 2022-03-03
AU2013336409B2 (en) 2017-08-03
MY169147A (en) 2019-02-18
KR102209395B1 (ko) 2021-01-28
US20150290342A1 (en) 2015-10-15
EP2911700A1 (en) 2015-09-02
IL237672A0 (en) 2015-04-30
DK2911700T3 (en) 2017-05-15
MX2015005122A (es) 2015-10-29
IL237672B (en) 2018-02-28
IN2015DN02349A (pt) 2015-08-28
SG11201501618WA (en) 2015-04-29
ES2623209T3 (es) 2017-07-10

Similar Documents

Publication Publication Date Title
BR112015008376A2 (pt) conjugados fármaco-proteína
BR112015008311A2 (pt) conjugados fármaco-proteína
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
BR112017018521A2 (pt) conjugados de fármacos compreendendo anticorpos contra claudin18.2
BR112013021562A2 (pt) anticorpos para cd70
BR112017014328A2 (pt) anticorpos compreendendo um domínio de ligação de antígeno dependente de concentração de íon, variantes de região fc, anticorpos de ligação à il-8, métodos de produção dos mesmos e para prolongamento ou redução da meia-vida de um anticorpo em plasma, composição farmacêutica, ácido nucleico, vetor, célula hospedeira
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
GT201200271A (es) Proteínas que se unen al tnf-a
BR112013003262A2 (pt) anticorpos melhorados da classe igg4.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BRPI0911431B8 (pt) composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
BR112012017124B8 (pt) método para produzir e para purificar um multímero polipeptídico
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
UA113712C2 (xx) Антитіло до fap і способи його застосування
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
BR112014030098A2 (pt) métodos de rotulagem específica de sítio e moléculas produzidas pelos mesmos
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01)

B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]